Aurinia Completes NDA and Requests Priority Review of Voclosoporin by FDA for Lupus Nephritis
May 28, 2020
The Lupus Research Alliance is pleased to share that Aurinia Pharmaceuticals Inc submitted a New Drug Application...
voclosporin
Aurinia Moves Voclosporin Closer to FDA Approval for Lupus Nephritis
March 16, 2020
The Lupus Research Alliance is pleased to share an announcement from Aurinia Pharmaceuticals that moves its potential...
LRA Celebrates Major Research Breakthroughs in 2019
January 7, 2020
2019 was a phenomenal, breakthrough year for lupus research on both the clinical development and basic science...
Potential Lupus Nephritis Treatment Works Well with Mycophenolate Acid
November 8, 2019
Aurinia Pharmaceuticals announced results from a study showing that their investigational drug voclosporin did not significantly impact...
Good News from Aurinia Pharmaceuticals for Lupus Nephritis
September 25, 2018
Congratulations to Aurinia Pharmaceuticals for completing patient enrollment in the AURORA Phase 3 clinical trial ahead of...
Aurinia Announces Voclosporin Meets 48-Week Remission Endpoints
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a clinical stage biopharmaceutical company focused on the global...